$FATE News

Fate Therapeutics To Feature Data From Off-The-Shelf CAR T-Cell Programs At 2026 ASCO And EULAR Annual Meetings

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

Fate Therapeutics Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $1.299M Beat $1.139M Estimate

Fate: 'Hold' FT819 Regimen B Dosing And Potential FDA Alignment In H2 2026

Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting

Fate Therapeutics To Present Data For Its Off-The-Shelf CAR T-Cell Programs At American Society Of Gene And Cell Therapy Annual Meeting

Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Novavax (NVAX) Reports Q1 Loss, Beats Revenue Estimates

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

Fate Therapeutics' FT819 Selected By FDA As Participant In Chemistry, Manufacturing And Controls Development And Readiness Pilot Program To Treat Moderate To Severe Systemic Lupus Erythematosus

Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

Fate Therapeutics Announces That Data From Its Off-The-Shelf CAR T-Cell Programs FT819, FT839 And FT836 Will Be Featured At The American Society Of Gene And Cell Therapy Annual Meeting, May 11–15

HC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $7

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting

Fate Therapeutics To Present Clinical Data From Its FT819 Candidate At Congress Of Clinical Rheumatology In Florida

Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting

Fate Therapeutics Says Preclinical Data From Next-Gen, Off-The-Shelf CAR T-Cell Product Candidate, FT839, To Be Featured At 2026 AACR Annual Meeting

Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference

Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences